Candela offers physicians program to trade-up from Photoderm-VL.WAYLAND, Mass.--(BUSINESS WIRE)--Feb. 26, 1996--Candela Corp. (CLZR) announced today that it would grant substantial discounts to current ESC See escape character and escape key. See also ESC/P. ESC - escape device users to trade up to the newest longpulse ScleroLASER technology. Under the program, any physician who has previously purchased an ESC Photoderm-VL device can now trade in this nonselective, incoherent light source device and receive a substantial discount on the latest, most effective system for the treatment of leg veins. Candela candela (kăndĕ`lə), in weights and measures: see candle. A unit of measurement of the intensity of light. Part of the SI system of measurement, one candela (cd) is the monochromatic radiation of 540THz with a radiant intensity stated that recently industry reports suggest that "...significant and irreversible tissue damage(a)" is a potential adverse effect associated with nonselective, light source devices such as the Photoderm-VL. Gerard E. Puorro, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Candela, stated, "We believe that informed physicians should have the opportunity to choose the most advanced and efficacious ef·fi·ca·cious adj. Producing or capable of producing a desired effect. See Synonyms at effective. [From Latin effic technology for the safety and benefit of their leg vein patients." The ScleroLASER was introduced at the American Academy of Dermatology The American Academy of Dermatology (AAD) is the largest organization of dermatologists in the world. The Academy grants Fellowships and Associate Memberships, as well as Fellowships for Nonresidents (of the United States of America or Canada). meeting this month in Washington, D.C. "Physicians interested in upgrading their leg vein technology can avail themselves of the Candela trade-up opportunity anytime on or before June 30, 1996," Puorro noted. The ScleroLASER was cleared by the Food and Drug Administration in April of 1995 and has been in ongoing clinical investigations. An additional FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance was received in January for protocols enabling the use of higher energies during treatments. These higher fluences offer an even more effective treatment with no long-term adverse effects. Interested physicians may request trade-up program applications forms by contacting Anne Engelson at 800/733-8550, x279. (a) Medical Laser Insight (1/96) CONTACT: Jane Smith Manager, MarCom 508/358-7637 x247 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion